WASHINGTON – The U.S. Food and Drug Administration is alerting the public about an increased risk of serious heart-related problems and cancer with the arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib) compared to another type of medicine called tumor necrosis factor (TNF) inhibitors.
The FDA required the safety trial, which also investigated other potential risks, including blood clots in the lungs and death.
Those final results are not yet available. “We will evaluate the clinical trial results we have received to date and will work with the drug manufacturer to obtain further information as soon as possible,” the FDA said Thursday in a news release. “We will communicate our final conclusions and recommendations
Read more on clickorlando.com